For this recent evidence, SIRT1 activation is emerging as a novel therapeutic strategy for patients with MDs and drugs capable of activating the SIRT1/PGC-1α pathway may have positive effects in MD. Here, SIRT1 is linked to myelodysplastic syndrome.